NaPro, Bristol-Myers cancer news

NPRO amended its suit filed in September in the U.S. District Court for the District of Colorado claiming that BMY infringed its U.S. Patents Nos. 5,972,992 and 5,977,164 related to paclitaxel to include U.S. Patent No. 6,140,359, which covers injectable paclitaxel (see BioCentury, Sept. 25). ...